Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH in Unexplained Recurrent Pregnancy Loss
NCT06484634Completed
- Sponsor
- RESnTEC (Research and Technology) Ltd
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of low molecular weight heparin calcium in recurrent pregnancy loss (RPL) (2 arms), sponsored by RESnTEC (Research and Technology) Ltd. Primary endpoint: Efficacy of Low-Molecular-Weight Heparin (Live Birth Rate) at 32 weeks. Started Dec 2023; status: completed.
02
Drugs
low molecular weight heparin calcium
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT06484634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484634.